Skip to content

Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative Disease

Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03330470
Enrollment
26
Registered
2017-11-06
Start date
2017-01-01
Completion date
2023-09-30
Last updated
2025-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers, Mild Cognitive Impairment, Parkinson Disease, Subjective Cognitive Impairment

Keywords

Parkinson's disease, exercise training, motor functions, cognitive functions

Brief summary

The purpose of this study is to investigate the beneficial effects of regular exercise and the impact of food supplement carnosine on cognitive, motoric and metabolic functions as well as on specific biologically active substances in volunteers with subjective (SCI) or mild (MCI) cognitive impairment, as well as in patients in early stages of Parkinson's disease. The investigators assume the immediate intervention-associated health benefit for volunteers.

Detailed description

Standard Operating Procedures for patient recruitment, data collection, data management, data analysis routinely used in Biomedical Research Center, Slovak Academy of Sciences, University Hospital Bratislava and Comenius University, Bratislava will be employed. Gait and balance parameters will be examined and analysed at the Department of Behavioural Neuroscience, Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovakia Statistical analysis will be employed to address the primary and secondary objectives, as specified in the study protocol.

Interventions

BEHAVIORALexercise

participants will be subjected to 4 months supervised exercise intervention

DIETARY_SUPPLEMENTcarnosine supplementation

participants will be instructed to take carnosine 2 times daily

BEHAVIORALstretching

participants will be subjected to 4 months supervised stretching program

participants will be instructed to take placebo 2 times daily

Sponsors

Comenius University
CollaboratorOTHER
University Hospital Bratislava
CollaboratorOTHER
National Cheng Kung University
CollaboratorOTHER
Slovak Academy of Sciences
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
55 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Signed informed consent * Age 55 - 80 years * Presence of Subjective Cognitive Impairment (SCI), Mild Cognitive Impairment (MCI) or early stage of Parkinson's Disease (Hoehn-Yahr 1st-2nd stage), assessed by experienced neurologist

Exclusion criteria

* Serious systemic cardiovascular, hepatic, renal disease, cancer * Lack of compliance

Design outcomes

Primary

MeasureTime frameDescription
glucose toleranceup to 36 monthschanges in glucose tolerance will be determined with oral glucose tolerance test (2h glucose, mmol/l)
learning/working memoryup to 36 monthsexercise related changes in learning/working memory will be determined with the aid of Addenbrook's cognitive test (maximum test score 100)
Balance parameter (Berg Balance Scale)up to 36 monthsExercise related changes in ballance will be examined with the Berg Balance Scale test (max score 56)

Secondary

MeasureTime frameDescription
Gait parameter (Stance time)24 monthsStance time will be evaluated in a subset of PD individuals, (once the technology for gait analysis will be available to the study investigators). Stance time - duration within the gait cycle when the measured leg is in contact with the ground. Measured using Microsoft Kinect for Azure as the time from when ankle joint speed in the anterior-posterior direction drops below 10% of its peak to reaching 10% in the next gait cycle, unit measure (s)
Gait parameter (step length)24 monthsStep length - linear distance in the anterior-posterior direction between consecutive heel strikes of opposite feet (m); measured using Microsoft Kinect for Azure as the peak distance between left and right ankle points. In a subpopulation of PD patients after (Azure Kinect) technology is available.
Postural parameter (magnitude of CoP displacement)24 monthsMagnitude of centre of pressure (CoP) displacement - exercise-related changes in CoP magnitude in both anterior-posterior and medial-lateral directions reflecting the whole body sway will be determined with the aid of force platform (mm)
Postural parameter (Velocity CoP displacement)24 monthsVelocity of centre of pressure (CoP) displacement - exercise-related changes in CoP velocity in both anterior-posterior and medial-lateral directions reflecting the whole body sway will be determined with the aid of force platform (mm/s)
Postural Sway Area24 monthsPostural sway area - exercise-related changes in the overall centre of pressure (CoP) displacement over a period of time computed as the area enclosed by the CoP path per unit of time will be determined with the aid of force platform (mm-2.s-1)
Postural sway path length24 monthsPostural sway path length - exercise-related changes in the overall centre of pressure (CoP) displacement computed as the total distance the CoP travels will be determined with the aid of force platform (mm)
habitual physical activityup to 36 monthsHabitual physical activity will be determined with accelerometers
Acceleration of upper and lower trunk24 monthsAcceleration of upper and lower trunk - exercise-related changes in acceleration of upper and lower trunk in both anterior-posterior and medial-lateral directions reflecting the upper body sway will be determined with the aid of inertial sensors with inbuilt 3D accelerometers (m-2)
Upper and lower trunk sway area24 monthsUpper and lower trunk sway area - exercise-related changes in the overall acceleration of upper and lower trunk over a period of time computed as the area enclosed by the acceleration path per unit of time will be determined with the aid of inertial sensors with inbuilt 3D accelerometers (m-2.s-5)
Upper and lower trunk sway path24 monthsUpper and lower trunk sway path - exercise-related changes in the overall acceleration of upper and lower trunk computed as the total length of the acceleration path will be determined with the aid of inertial sensors with inbuilt 3D accelerometers (m.s-2)
Upper and lower trunk sway frequency24 monthsUpper and lower trunk sway frequency - exercise-related changes in the rate of upper and lower trunk acceleration in both anterior-posterior and medial-lateral directions will be determined with the aid of inertial sensors with inbuilt 3D accelerometers using time-domain and frequency domain analyses (Hz)
Upper and lower trunk sway jerkiness24 monthsUpper and lower trunk sway jerkiness - exercise-related changes in the jerk of upper and lower trunk computed as a time derivative of upper and lower trunk acceleration will be determined with the aid of inertial sensors with inbuilt 3D accelerometers (m-2.s-5)
Angular velocity of upper and lower trunk24 monthsAngular velocity of upper and lower trunk - exercise-related changes in angular velocity of upper and lower trunk in both anterior-posterior and medial-lateral directions will be determined with the aid of inertial sensors with inbuilt 3D gyroscopes (rad.s-1)
Postural sway frequency24 monthsPostural sway frequency - exercise-related changes in the rate of the centre of pressure (CoP) oscillations in both anterior-posterior and medial-lateral directions will be determined with the aid of force platform using time-domain and frequency domain analyses (Hz)
physical fitnessup to 36 monthsSubmaximal aerobic capacity will be determined with one mile (Rockport) walk test
Gait parameters (Walking speed)24 monthsWalking (gait) speed will be evaluated in a subset of PD individuals with the Azure Kinect depth camera (once the technology for gait analysis will be available to the study investigators). An average walking velocity will be computed as total distance divided by time of the test (m·s-¹); measured using Microsoft Kinect for Azure

Countries

Slovakia, Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026